Immatics N.V. (IMTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
IMTX POWR Grades
- IMTX scores best on the Growth dimension, with a Growth rank ahead of 99.33% of US stocks.
- The strongest trend for IMTX is in Value, which has been heading up over the past 179 days.
- IMTX's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).
IMTX Stock Summary
- IMTX's went public 3.48 years ago, making it older than merely 11.27% of listed US stocks we're tracking.
- IMTX's price/sales ratio is 13.43; that's higher than the P/S ratio of 89.23% of US stocks.
- With a year-over-year growth in debt of 441.42%, Immatics NV's debt growth rate surpasses 96.83% of about US stocks.
- If you're looking for stocks that are quantitatively similar to Immatics NV, a group of peers worth examining would be VRNA, ARVN, CUE, ARGX, and ACRS.
- Visit IMTX's SEC page to see the company's official filings. To visit the company's web site, go to www.immatics.com.
IMTX Stock Price Chart Interactive Chart >
IMTX Price/Volume Stats
|Current price||$7.06||52-week high||$16.30|
|Prev. close||$6.61||52-week low||$5.75|
|Day high||$7.11||Avg. volume||147,135|
|50-day MA||$7.71||Dividend yield||N/A|
|200-day MA||$10.76||Market Cap||444.14M|
Immatics N.V. (IMTX) Company Bio
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors; and IMA204, an anti-tumor therapy that targets the malignant tumor cell. Its TCR Bispecifics product candidates include IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid and hematological malignancies. The company also develops IMA101, a multi-target precision immunotherapy; and IMA301, an off-the-shelf ACT. It has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in TÃ¼bingen, Germany.
Most Popular Stories View All
IMTX Latest News Stream
|Loading, please wait...|
IMTX Latest Social Stream
View Full IMTX Social Stream
Latest IMTX News From Around the Web
Below are the latest news stories about Immatics NV that investors may wish to consider to help them evaluate IMTX as an investment opportunity.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Wall Street brokerages predict that Immatics (NASDAQ:IMTX) will post sales of $84.78 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Immatics earnings, with the highest sales estimate coming in at $158.99 million and the lowest estimate coming in at $10.56 million. The business is scheduled to announce 
Celebrations may be in order for Immatics N.V. ( NASDAQ:IMTX ) shareholders, with the analysts delivering a significant...
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cidara Therapeutics (CDTX – Research Report) and Immatics (IMTX – Research Report) with bullish sentiments. Cidara Therapeutics (CDTX) In a report released today, Joseph Stringer from Needham reiterated a Buy rating on Cidara Therapeutics, with a price target of $6.00. The company's shares closed last Tuesday at $1.20. According to TipRanks.
The pharma has expanded an alliance with a German biotech by paying $150 million for a drug candidate that executives hope can have "cell therapy-like efficacy" for solid tumors.
IMTX Price Returns